Osteoarthritis: The Challenge of Establishing a Personalised Treatment

Osteoarthritis: The Challenge of Establishing a Personalised Treatment

The symposium, co-chaired by Prof Johanne Martel-Pelletier and Prof Antonello Pietrangelo, opened with a discussion of metabolic syndrome-associated osteoarthritis (OA) and a brief overview of treatment options by Prof Francis Berenbaum. Prof Jean-Pierre Pelletier then discussed the use of symptomat...

Full description

Bibliographic Details
Main Authors: Johanne Martel-Pelletier, Antonello Pietrangelo, Francis Berenbaum, Jean-Pierre Pelletier, Burkhard Leeb
Format: Article
Language:English
Published: European Medical Journal 2014-06-01
Series:European Medical Journal Rheumatology
Subjects:
EULAR
European League Against Rheumatism
Online Access:http://emjreviews.com/wp-content/uploads/Osteoarthritis-The-Challenge-Of-Establishing-A-Personalised-Treatment.pdf
id doaj-b9f6e9d5d38a40b1b031cd8f0edd2d35
record_format Article
spelling doaj-b9f6e9d5d38a40b1b031cd8f0edd2d352020-11-25T01:46:05ZengEuropean Medical JournalEuropean Medical Journal Rheumatology2056-63952014-06-01113339Osteoarthritis: The Challenge of Establishing a Personalised TreatmentJohanne Martel-Pelletier0Antonello Pietrangelo1Francis Berenbaum2Jean-Pierre Pelletier3Burkhard Leeb4Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada Unit of Internal Medicine and Metabolic Diseases, Centre for Hemochromatosis University Hospital, Modena, ItalyUniversity Pierre & Marie Curie, INSERM UMR-S938, AP-HP Saint-Antoine Hospital, Paris, France Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada2nd Department of Medicine, Centre for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, AustriaThe symposium, co-chaired by Prof Johanne Martel-Pelletier and Prof Antonello Pietrangelo, opened with a discussion of metabolic syndrome-associated osteoarthritis (OA) and a brief overview of treatment options by Prof Francis Berenbaum. Prof Jean-Pierre Pelletier then discussed the use of symptomatic slow-acting drugs for OA (SYSADOA) for knee OA within the context of the new European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommendations. Finally, Dr Burkhard Leeb concluded the session by discussing the indications, contraindications, and side-effect management of diacerein.http://emjreviews.com/wp-content/uploads/Osteoarthritis-The-Challenge-Of-Establishing-A-Personalised-Treatment.pdfEULAREuropean League Against Rheumatism
collection DOAJ
language English
format Article
sources DOAJ
author Johanne Martel-Pelletier
Antonello Pietrangelo
Francis Berenbaum
Jean-Pierre Pelletier
Burkhard Leeb
spellingShingle Johanne Martel-Pelletier
Antonello Pietrangelo
Francis Berenbaum
Jean-Pierre Pelletier
Burkhard Leeb
Osteoarthritis: The Challenge of Establishing a Personalised Treatment
European Medical Journal Rheumatology
EULAR
European League Against Rheumatism
author_facet Johanne Martel-Pelletier
Antonello Pietrangelo
Francis Berenbaum
Jean-Pierre Pelletier
Burkhard Leeb
author_sort Johanne Martel-Pelletier
title Osteoarthritis: The Challenge of Establishing a Personalised Treatment
title_short Osteoarthritis: The Challenge of Establishing a Personalised Treatment
title_full Osteoarthritis: The Challenge of Establishing a Personalised Treatment
title_fullStr Osteoarthritis: The Challenge of Establishing a Personalised Treatment
title_full_unstemmed Osteoarthritis: The Challenge of Establishing a Personalised Treatment
title_sort osteoarthritis: the challenge of establishing a personalised treatment
publisher European Medical Journal
series European Medical Journal Rheumatology
issn 2056-6395
publishDate 2014-06-01
description The symposium, co-chaired by Prof Johanne Martel-Pelletier and Prof Antonello Pietrangelo, opened with a discussion of metabolic syndrome-associated osteoarthritis (OA) and a brief overview of treatment options by Prof Francis Berenbaum. Prof Jean-Pierre Pelletier then discussed the use of symptomatic slow-acting drugs for OA (SYSADOA) for knee OA within the context of the new European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommendations. Finally, Dr Burkhard Leeb concluded the session by discussing the indications, contraindications, and side-effect management of diacerein.
topic EULAR
European League Against Rheumatism
url http://emjreviews.com/wp-content/uploads/Osteoarthritis-The-Challenge-Of-Establishing-A-Personalised-Treatment.pdf
work_keys_str_mv AT johannemartelpelletier osteoarthritisthechallengeofestablishingapersonalisedtreatment
AT antonellopietrangelo osteoarthritisthechallengeofestablishingapersonalisedtreatment
AT francisberenbaum osteoarthritisthechallengeofestablishingapersonalisedtreatment
AT jeanpierrepelletier osteoarthritisthechallengeofestablishingapersonalisedtreatment
AT burkhardleeb osteoarthritisthechallengeofestablishingapersonalisedtreatment
_version_ 1725020987925200896

Similar Items